# US 2021/0171530 A1 · Ion channel modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171530 A1
- Document ID: US20210171530A1
- Status: Published application
- Kind: A1
- Application number: 17/104,512
- Filed: 2020-11-25
- Published: 2021-06-10
- Earliest claimed: 2019-11-26
- Assignees: Praxis Precision Medicines, Inc.
- Applicants: Praxis Precision Medicines, Inc.
- Inventors: Kiran Reddy; Gabriel Martinez Botella; Andrew Mark Griffin; Brian Edward Marron; Carlos Loya
- Web page: https://patentgrep.com/patent/US20210171530A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A compound having the Formula II-II:
or a pharmaceutically acceptable salt thereof, wherein
R1 is halo;
R2 is C1-4haloalkyl;
R3 and R4 are each independently hydrogen or C1-4alkyl; or R3 and R4 together with the carbon attached to R3 and R4 form a C3-6carbocyclyl;
R5 is C1-4alkyl; and
t is 0 or 1.

### Claim at position 3

27-28. (canceled)

### Claim 29 (depends on 26)

The compound of claim 26, wherein R1 is fluoro.

### Claim 30 (depends on 26)

The compound of claim 26, wherein R2 is CF3.

### Claim at position 6

31-32. (canceled)

### Claim 33 (depends on 26)

The compound of claim 26, wherein R3 and R4 are each methyl.

### Claim 34 (depends on 26)

The compound of claim 26, wherein R3 and R4 together with the carbon attached to R3 and R4 form cyclobutyl.

### Claim 35 (depends on 26)

The compound of claim 26, wherein R5 is methyl or ethyl.

### Claim at position 10

36-37. (canceled)

### Claim 38 (depends on 26)

The compound of claim 26, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim at position 12

39-56. (canceled)

### Claim 57

A compound of Formula (III-II):
or a pharmaceutically acceptable salt thereof, wherein:
R7 is a monocyclic C3-6 cycloalkyl substituted with one or more Ra;
R5 is selected from the group consisting of halo, C3-6 cycloalkyl, and C1-4alkyl optionally substituted with O—C1-4alkyl or O—C3-6 cycloalkyl;
R6 is C1-4alkyl or C1-4haloalkyl, wherein the C1-4alkyl or C1-4haloalkyl is each substituted with ORc;
m is 0, 1, or 2;
Ra is selected from the group consisting of halo, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, and C1-4haloalkoxy; and
Rc is C1-4alkyl optionally substituted with C3-6 cycloalkyl or phenyl, or C3-6 cycloalkyl.

### Claim at position 14

58-62. (canceled)

### Claim 63 (depends on 57)

The compound of claim 57, wherein the compound is a compound of Formula (III-II-f):
wherein n is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt thereof.

### Claim 64 (depends on 57)

The compound of claim 57, wherein R7 is cyclopropyl.

### Claim 65 (depends on 57)

The compound of claim 57, wherein R5 is C1-4alkyl.

### Claim at position 18

66-68. (canceled)

### Claim 69 (depends on 57)

The compound of claim 57, wherein R6 is C1-4haloalkyl substituted with ORc.

### Claim at position 20

70-72. (canceled)

### Claim 73 (depends on 57)

The compound of claim 57, wherein the compound is selected the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 74

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 75 (depends on 74)

A pharmaceutical composition comprising a compound of claim 74, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 76 (depends on 74)

A method of treating a condition relating to aberrant function of a sodium ion channel in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 74, or a pharmaceutically acceptable salt thereof.

### Claim 77 (depends on 76)

The method of claim 76, wherein the condition is a neurological or psychiatric disorder.

### Claim 78 (depends on 77)

The method of claim 77, wherein the disorder is epilepsy or an epilepsy syndrome.

### Claim at position 27

79-82. (canceled)

### Claim 83 (depends on 76)

The method of claim 76, wherein the condition is selected from the group consisting of epileptic encephalopathy, epileptic encephalopathy with SCN1A, SCN2A, SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, sudden unexpected death in epilepsy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, sudden expected death in epilepsy (SUDEP), KCNQ2 epileptic encephalopathy, and KCNT1 epileptic encephalopathy.

### Claim at position 29

84-85. (canceled)

### Claim 86 (depends on 74)

A method of treating or preventing a trigeminal autonomic cephalalgia (TAC) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 74, or a pharmaceutically acceptable salt thereof, wherein the TAC is selected from the group consisting of paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and long-lasting autonomic symptoms with hemicrania.

### Claim at position 31

87-100. (canceled)
